retatrutide peptide clinical trial results Peptide Series #3 — Retatrutide

The most common include nausea, vomiting, diarrhea, abdominal pain, and constipation

The confusion comes from rapid water weight fluctuations in the first 2-3 weeks after stopping

Every range requires a different approach

Helps maintain healthy blood sugar

As an alarming finding, the activation of GLP-1R has been associated with developing thyroid cancer [64, 65]

Unlike approved agents such as semaglutide (Wegovy) or tirzepatide (Zepbound), retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the United Kingdom